RECRUITING

Trial of Precision Medicine in Emergency Departments

Description

The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases ED return visits and hospitalizations. We will conduct a randomized, controlled, pragmatic clinical trial assessing both the real-world effectiveness as well as implementation outcomes using a targeted PGx testing panel in several UF Health EDs.

Study Overview

Study Details

Study overview

The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases ED return visits and hospitalizations. We will conduct a randomized, controlled, pragmatic clinical trial assessing both the real-world effectiveness as well as implementation outcomes using a targeted PGx testing panel in several UF Health EDs.

Trial of Precision Medicine in Emergency Departments

Trial of Precision Medicine in Emergency Departments

Condition
Pharmacogenomic Drug Interaction
Intervention / Treatment

-

Contacts and Locations

Gainesville

UF Health Emergency Department, Gainesville, Florida, United States, 32610

Jacksonville

UF Health Jacksonville Downtown Emergency Department, Jacksonville, Florida, United States, 32209

Jacksonville

UF Health Jacksonville North Emergency Department, Jacksonville, Florida, United States, 32218

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults (18 years or older) presenting to a participating ED
  • 2. Diagnosis or suspicion of a condition that might be treated by a PGx drug (See Table 3).
  • 3. Documentation of a prior ED visit within the past 6 months
  • 1. Patients with prior clinical pharmacogenetic test results within the EHR for genes relevant for this study
  • 2. Any medical condition that would prohibit the ability to complete the study
  • 3. Life expectancy less than 6 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Florida,

Julio D Duarte, Pharm.D., Ph.D., PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2027-07-01